VIDEO: DESTINY-Lung01 results are 'exciting development' in treatment of lung cancer subset
Click Here to Manage Email Alerts
In this video, Pasi A. Jänne, MD, PhD, director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School, discusses results from the DESTINY-Lung01 study presented at ESMO 2021.
“The DESTINY-Lung study evaluated trastuzumab deruxtecan, a HER2 antibody drug conjugate in patients with HER2 [mutated] lung cancer,” Jänne told Healio, adding that there are currently no approved targeted therapies for these patients.
He said that while other therapies have been assessed among this subset of lung cancer patients, “trastuzumab deruxtecan stands above all of those tested in the past.”
In the phase II trial, Jänne and colleagues found that among patients with HER2-mutated NSCLC treated with trastuzumab deruxtecan, there was a response rate of approximately 55% and a median progression-free survival rate of 8.2 months.
“It’s an exciting development for this particular subset of patients [with lung cancer],” Jänne said. “HER2 mutations are something we find on comprehensive genetic testing — that’s standard of care now in lung cancer — and this certainly opens a therapeutic option for this group of patients, and hopefully will receive regulatory approval in the near future as well.”
Collapse
Click Here to Manage Email Alerts